IncobotulinumtoxinA is the third botulinum neurotoxin type A (BoNTA) to be approved for aesthetic use in the United States. This article introduces the new product with an overview of clinical applications and a discussion of the neurotoxin's molecular structure. The role and clinical relevance of complexing proteins in BoNTA products are discussed. Finally, incobotulinumtoxinA's mechanism of action is described.
|Original language||English (US)|
|Journal||Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery|
|Issue number||1 Suppl|
|State||Published - Mar 2013|
ASJC Scopus subject areas